Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency

Journal of Clinical Pathology

Volumn 63, Issue 9, 2010, Pages 846-847

  Knight, Emma ^a   Carne, Emily ^a   Novak, Barbara ^b   El Shanawany, Tariq ^a   Williams, Paul ^a   Pickersgill, Trevor ^a   Jolles, Stephen ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIDASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

ADULT; ASTHMA; BODY WEIGHT; CASE REPORT; CHEST INFECTION; DRUG HALF LIFE; DRUG SELF ADMINISTRATION; DYSARTHRIA; ERYTHEMA; FEMALE; HOME CARE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; LETTER; MITOCHONDRIAL MYOPATHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; PRIORITY JOURNAL; SINUSITIS; TREMOR;

ADULT; COMMON VARIABLE IMMUNODEFICIENCY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNIZATION, PASSIVE; INJECTIONS, SUBCUTANEOUS; SELF ADMINISTRATION;

EID: 77956901227     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.076828     Document Type: Letter

References (10)

1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8.
2. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007;21:105-16. (Pubitemid 46624555)
3. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm 1990;9:509-29.
4. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009;158(Suppl 1):51-9.
5. Schiff RI, et al. Recombinant human hyaluronidase facilitates dispersion of subcutaneously administered gammagard liquid, enabling administration of full monthly dose in single site with improved bioavailability in immunodeficient patients. Clin Exp Immunol 2008;154(Suppl 1):121-2.
6. Schiff RI, et al. Pharmacokinetic properties of gammagard liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases (PID). Clin Exp Immunol 2008;154(Suppl 1):132.
7. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40.
8. Thomas JR, Yocum RC, Haller MF, et al. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 2007;10:1312-20.
9. Allen CH, Etzwiler LS, Miller MK, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 2009;124:e858-67.
10. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631-8.